Low-Dose Naltrexone Could Ease Long COVID Symptoms

A study suggests the drug may help adults with long COVID manage fatigue and brain fog, though further research is required.

Updated on Oct. 26, 2026 in COVID-19

Gouache-painted illustration of a single medical vial containing small white tablets, rendered in a restrained, quiet style. — A retrospective study of 230 adults suggests that low-dose naltrexone may help reduce debilitating fatigue and brain fog symptoms for long COVID patients. AI Illustration. Upload story photo >

Live Poll

Should medical research prioritize repurposing existing, low-cost medications to treat new health conditions?

A retrospective study of 230 adults suggests that low-dose naltrexone may help reduce symptoms for some individuals with long COVID. Findings indicate improvements in fatigue, brain fog, and sleep quality for patients treated between 2023 and 2025.

Why it matters

As 6.9% of U.S. adults reported experiencing long COVID in 2022, identifying potential treatments remains a critical focus for clinical care. This research provides early observations for a patient population that currently lacks standardized, effective therapeutic options.

This retrospective study analyzed electronic health records for 230 adults, showing an average annual decrease of 5.1 points in symptom composite scores versus a baseline of 20. These results remain preliminary, as randomized, placebo-controlled trials are required to confirm the findings.

The players

Stanford Long COVID Clinic

A clinical and research facility that specializes in the management and study of post-COVID conditions.

The details

Investigators at the Stanford Long COVID Clinic suggest naltrexone may function through anti-inflammatory and immunomodulatory pathways to mitigate lingering COVID symptoms. Over the study period, patients taking a median dose of 4 mg of naltrexone reported meaningful relief from fatigue, brain fog, and post-exertional malaise. The data did not show significant improvement for symptoms such as headache or lightheadedness, and further research is necessary to understand the medication's specific impact.

2022 marked the year 6.9% of U.S. adults reported experiencing long COVID.
2023 to December 2025 served as the data collection period for the Stanford Long COVID Clinic.

Health Landscape

This study aligns with the broader mission of the Stanford Long COVID Clinic to address the lack of established treatments for millions of Americans with persistent symptoms. It represents a shift toward evaluating existing medications for repurposing to manage the chronic nature of long COVID.

If you are managing long COVID, these findings highlight potential treatment avenues that are worth discussing with your primary care physician or a specialist. Because this was a retrospective study, it is important to wait for clinical trial data to understand whether this approach is appropriate for your specific health needs.

The takeaway

While early data on naltrexone for long COVID is promising, patients should view these results as preliminary rather than a definitive treatment. Focus on tracking specific symptom patterns and discussing the full range of current, evidence-based management options during your next medical visit.